Cargando…
A learning health system approach to the COVID‐19 pandemic: System‐wide changes in clinical practice and 30‐day mortality among hospitalized patients
INTRODUCTION: Rapid, continuous implementation of credible scientific findings and regulatory approvals is often slow in large, diverse health systems. The coronavirus disease 2019 (COVID‐19) pandemic created a new threat to this common “slow to learn and adapt” model in healthcare. We describe how...
Autores principales: | McCreary, Erin K., Kip, Kevin E., Bariola, J. Ryan, Schmidhofer, Mark, Minnier, Tami, Mayak, Katelyn, Albin, Debbie, Daley, Jessica, Linstrum, Kelsey, Hernandez, Erik, Sackrowitz, Rachel, Hughes, Kailey, Horvat, Christopher, Snyder, Graham M., McVerry, Bryan J., Yealy, Donald M., Huang, David T., Angus, Derek C., Marroquin, Oscar C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284933/ https://www.ncbi.nlm.nih.gov/pubmed/35860323 http://dx.doi.org/10.1002/lrh2.10304 |
Ejemplares similares
-
Emergency department implementation of monoclonal antibody infusion for the treatment of coronavirus disease 2019: A template for rapid deployment
por: Woltemate, Thomas J., et al.
Publicado: (2021) -
Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days
por: McCreary, Erin K., et al.
Publicado: (2022) -
Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19
por: McCreary, Erin K., et al.
Publicado: (2022) -
Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era
por: McCreary, Erin K, et al.
Publicado: (2022) -
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization
por: Huang, David T., et al.
Publicado: (2021)